BARINTHUS Trademark

Trademark Overview


On Monday, January 8, 2024, a trademark application was filed for BARINTHUS with the United States Patent and Trademark Office. The USPTO has given the BARINTHUS trademark a serial number of 79392428. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, February 20, 2025. This trademark is owned by Barinthus Biotherapeutics (UK) Limited. The BARINTHUS trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical substances for the treatment of cancer, infectious diseases, and autoimmune diseases; pharmaceutical substances for the prevention of cancer, infectious diseases, and autoimmune diseases; pharmaceutical preparations for the treatment of cancer, infectious diseases, and autoimmune diseases; pharmaceutical preparations for the prevention of cancer, infectious diseases, and autoimmune diseases; pharmaceutical products for the treatment of cancer, infectious diseases, and autoimmune diseases; pharmaceutical products for the prevention of cancer, infectious diseases, and autoimmune diseases; pharmaceutical substances, pharmaceutical preparations and pharmaceutical products for the induction of immune tolerance, namely, pharmaceutical preparations for the treatment of immune system related diseases and disorders; immunotherapeutics, namely, pharmaceutical products for the treatment of cancer and infectious diseases, and autoimmune diseases; immunotherapeutics, namely, pharmace...
barinthus

General Information


Serial Number79392428
Word MarkBARINTHUS
Filing DateMonday, January 8, 2024
Status681 - PUBLICATION/ISSUE REVIEW COMPLETE
Status DateThursday, February 20, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 11, 2025

Trademark Statements


Goods and Servicespharmaceutical substances for the treatment of cancer, infectious diseases, and autoimmune diseases; pharmaceutical substances for the prevention of cancer, infectious diseases, and autoimmune diseases; pharmaceutical preparations for the treatment of cancer, infectious diseases, and autoimmune diseases; pharmaceutical preparations for the prevention of cancer, infectious diseases, and autoimmune diseases; pharmaceutical products for the treatment of cancer, infectious diseases, and autoimmune diseases; pharmaceutical products for the prevention of cancer, infectious diseases, and autoimmune diseases; pharmaceutical substances, pharmaceutical preparations and pharmaceutical products for the induction of immune tolerance, namely, pharmaceutical preparations for the treatment of immune system related diseases and disorders; immunotherapeutics, namely, pharmaceutical products for the treatment of cancer and infectious diseases, and autoimmune diseases; immunotherapeutics, namely, pharmaceutical products for the prevention of cancer and infectious diseases, and autoimmune diseases; vaccines; viral vaccines; vaccines for prevention against influenza; therapeutic vaccines for the treatment of influenza; vaccines for prevention against infectious diseases; therapeutic vaccines for the treatment of infectious diseases; vaccines for prevention against cancer; therapeutic vaccines for the treatment of cancer; viral antigens in the nature of biological tissue cultures for medical purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 1, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBarinthus Biotherapeutics (UK) Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Monday, April 1, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 5, 2024APPLICATION FILING RECEIPT MAILED
Monday, August 5, 2024NON-FINAL ACTION WRITTEN
Thursday, March 28, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 2, 2024ASSIGNED TO EXAMINER
Tuesday, August 6, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, August 15, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, August 15, 2024REFUSAL PROCESSED BY MPU
Thursday, February 13, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, February 13, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, February 13, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, February 13, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, February 13, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 13, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, February 13, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 13, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, February 19, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Sunday, September 1, 2024REFUSAL PROCESSED BY IB